肝胆胰领域中国之声亮相ASCO 2025，最新成果瞭望聚焦丨ASCO 2025

摘要：2025年美国临床肿瘤学会年会（2025 ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥盛大召开。日前，2025 ASCO入选摘要标题已发布。在肝胆胰恶性肿瘤领域，共有46项中国研究入选，包括1项快速口头报告、1项临床科学研讨会报告和44

编者按：2025年美国临床肿瘤学会年会（2025 ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥盛大召开。日前，2025 ASCO入选摘要标题已发布。在肝胆胰恶性肿瘤领域，共有46项中国研究入选，包括1项快速口头报告、1项临床科学研讨会报告和44项壁报（如有遗漏，欢迎留言补充）。这些成果不仅彰显了中国在该领域的创新活力，也为全球肿瘤防治提供了新的视角与思路。

快速口头报告

（Rapid Oral Abstract Session）

胃食管癌及肝胆胰癌专场

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

美国东部时间：6月2日11:30–13:00

北京时间：6月3日00:30–02:00

地点：Hall D2

摘要号: 4017

Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.

Claudin18.2（CLDN18.2）在胰腺导管腺癌（PDAC）中的表达及疗效：IBI343的I期剂量扩展队列研究结果

讲者: 虞先濬教授，复旦大学附属肿瘤医院

报告时间: 12:12-12:18

临床科学研讨会

（Clinical Science Symposium）

胰腺癌创新生物标志物与疫苗专场

Innovative Biomarkers and Vaccines in pancreatic cancer

美国东部时间：6月2日08:00–09:30

北京时间：6月2日21:00–22:30

地点：Hall D2

摘要号: 4010

Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies.

抗CCR8单克隆抗体caflekibart（LM-108）联合抗PD-1治疗胰腺癌患者的疗效与安全性：I/II期研究结果

讲者: 龚继芳教授，北京大学肿瘤医院

报告时间: 08:24-08:36

壁报

（Poster Session）

美国东部时间：5月31日09:00

北京时间：5月31日22:00

地点：Hall A

摘要号：4080；壁报号：BD 370

First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A.

Rilvegostomig （rilve）联合化疗一线治疗晚期胆道癌（BTC）：GEMINI-肝胆亚组研究2队列A的初步分析

讲者：周俭教授，复旦大学附属中山医院

摘要号：4084；壁报号：BD 374

Phase I study of Ori-C101, an armored GPC3-directed CAR-T, in patients with advanced hepatocellular carcinoma (HCC).

Ori-C101（靶向GPC3的CAR-T）治疗晚期肝细胞癌（HCC）的I期研究

讲者：Jieyi Shi 教授，复旦大学附属中山医院

摘要号：4087；壁报号：BD 377

HAIC plus TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma: The REACH-01 trial.

REACH-01研究：HAIC联合TAE、替雷利珠单抗及索凡替尼治疗不可切除肝内胆管癌

讲者：李康帅教授，山东大学齐鲁医院

摘要号：4088；壁报号：BD 378

Efficacy and safety of regorafenib combination with PD-1 inhibitors vs. regorafenib monotherapy in second-line treatment for patients with unresectable hepatocellular carcinoma after failure of different first-line treatments: A multicenter retrospective real-world study.

瑞戈非尼联合PD-1抑制剂对比瑞戈非尼单药二线治疗不同一线方案失败的不可切除肝细胞癌的疗效与安全性：多中心真实世界回顾性研究

讲者：Weihong Ma 教授，中国人民解放军总医院第五医学中心

摘要号：4090；壁报号：BD 380

TACE-HAlC combined with donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): A retrospective IPTW adjusted cohort study.

TACE-HAIC联合多纳非尼及免疫检查点抑制剂治疗BCLC C期肝细胞癌（THEME研究）：基于IPTW调整的回顾性队列分析

讲者：尹立楠教授，哈尔滨医科大学附属肿瘤医院

摘要号：4093；壁报号：BD 383

SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study.

SHR-8068联合阿得贝利单抗和贝伐珠单抗治疗晚期肝细胞癌（aHCC）的Ib/II期研究

讲者：刘连新教授；中国科学技术大学第一附属医院

摘要号：4094；壁报号：BD 384

Hepatic arterial infusion chemotherapy combined with donafenib and tislelizumab versus transcatheter chemoembolization alone for hepatocellular carcinoma: A propensity score matching study.

肝动脉灌注化疗联合多纳非尼和替雷利珠单抗对比单纯经导管化疗栓塞治疗肝细胞癌：倾向评分匹配研究

讲者：Tianqing Wu 教授；中山大学肿瘤防治中心

摘要号：4098；壁报号：BD 388

A prospective, observational phase II clinical study evaluating hepatic artery infusion chemotherapy in combination with HLX10 and HLX04 as first-line treatment for patients with advanced hepatocellular carcinoma.

肝动脉灌注化疗联合HLX10与HLX04一线治疗晚期肝细胞癌的前瞻性观察性II期临床研究

讲者：李慧锴教授，天津市肿瘤医院空港医院

摘要号：4100；壁报号：BD 390

Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: An update on SHATA-001 study.

SHATA-001研究结果更新：索拉非尼联合肝动脉灌注化疗对比索拉非尼联合经动脉化疗栓塞治疗晚期肝细胞癌

讲者：Zefeng Du 教授，中山大学肿瘤防治中心

摘要号：4104；壁报号：BD 394

Radiomic analysis on pretreatment MRI to predict response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicenter study.

基于治疗前MRI影像组学预测阿替利珠单抗联合贝伐珠单抗治疗晚期肝细胞癌疗效的多中心研究

讲者：孙惠川教授，复旦大学附属中山医院

摘要号：4105；壁报号：BD 395

Efficacy and safety of atezolizumab and bevacizumab with or without transarterial chemoembolization as first-line therapy for advanced hepatocellular carcinoma: An international multicenter real-world study.

阿替利珠单抗和贝伐珠单抗联合或不联合经动脉化疗栓塞一线治疗晚期肝细胞癌的疗效与安全性：一项国际多中心真实世界研究

讲者：张宁宁教授，天津市肿瘤医院

摘要号：4106；壁报号：BD 396

Factors associated with immunotherapy response for hepatocellular carcinoma.

肝细胞癌免疫治疗缓解的相关因素

讲者：Matthew Shing Hin Chung 教授，香港大学

摘要号：4107；壁报号：BD 397

Evolutionary divergence of the HLA-B genotype as a predictor of immune checkpoint inhibitor (ICI) therapy efficacy in hepatobiliary cancers.

HLA-B基因型进化差异预测肝胆肿瘤免疫检查点抑制剂（ICI）疗效

讲者：张楠教授，北京协和医院

摘要号：4108；壁报号：BD 398

Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumor burden and portal vein tumor thrombus.

肝动脉灌注化疗联合仑伐替尼及PD-1抑制剂一线治疗高肿瘤负荷合并门静脉癌栓肝细胞癌

讲者：Jiaxi Liu教授，中国医科大学附属第一医院

摘要号：4118；壁报号：BD 408

Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma: A multicenter real-world study.

初始不可切除肝内胆管癌的转化治疗：一项多中心真实世界研究

讲者：Xinhao Xiong, 教授，中山大学肿瘤防治中心

摘要号：4126；壁报号：BD 416

Transarterial chemoembolization plus donafenib and immune checkpoint inhibitors for intermediate hepatocellular carcinoma (CHANCE2410): A propensity score matching analysis.

经动脉化疗栓塞联合多纳非尼及免疫检查点抑制剂治疗中期肝细胞癌（CHANCE2410）：倾向评分匹配分析

讲者：仲斌演教授，浙江省肿瘤医院

摘要号：4127；壁报号：BD 417

Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing immune checkpoint inhibitor and concurrent antiviral prophylaxis agents: A prospective observational study.

接受免疫检查点抑制剂联合预防性抗病毒治疗的肝细胞癌患者乙肝病毒再激活：一项前瞻性观察性研究

讲者：Zefeng Du教授，中山大学肿瘤防治中心

摘要号：4128；壁报号：BD 418

Comparative analysis of ctDNA-MRD and MVI in predicting postoperative recurrence of hepatocellular carcinoma.

ctDNA-MRD与MVI预测肝细胞癌术后复发的对比分析

讲者：Jianan Feng 教授，南方医科大学珠江医院

摘要号：4131；壁报号：BD 421

Integration of cfDNA fragmentomics for early biliary tract cancer detection.

基于cfDNA片段组学整合分析实现胆道肿瘤早期检测

讲者：王吉文教授，复旦大学附属中山医院

摘要号：4133；壁报号：BD 423

Novel early-detection model based on cfDNA methylation and fragmentation features for liver cancer.

基于cfDNA甲基化与片段化特征的新型肝癌早筛模型

讲者：王小波教授，广西医科大学附属肿瘤医院

摘要号：4134；壁报号：BD 424

The efficacy and safety of donafenib as postoperative adjuvant therapy in patients at high risk of recurrence following radical resection of hepatocellular carcinoma (HCC): A multicenter retrospective study.

多纳非尼用于高复发风险肝细胞癌（HCC）患者根治性切除术后辅助治疗的疗效与安全性：一项多中心回顾性研究

讲者：饶建华教授，南京医科大学第一附属医院

摘要号：4136；壁报号：BD 426

Ultra-sensitive detection of hepatocellular carcinoma (HCC) with methylation signal enrichment of ctDNA and hepatitis B virus (HBV).

基于ctDNA甲基化信号富集与乙肝病毒（HBV）检测的超灵敏肝细胞癌诊断

讲者：林楠教授，中山大学附属第三医院

摘要号：4139；壁报号：BD 429

Neoadjuvant transhepatic arterial infusion chemotherapy (HAIC) with FOLFOX regime plus cadonilimab (PD-1/CTLA-4 bispecific antibody) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (CAR_Hero study).

肝动脉灌注化疗（HAIC）联合FOLFOX方案及卡度尼利单抗（PD-1/CTLA-4双抗）新辅助治疗可切除多结节性CNLC Ib/IIa期肝细胞癌（CAR_Hero研究）

讲者：Yongguang Wei 教授，广西医科大学第一附属医院

摘要号：4140；壁报号：BD 430

Prognostic significance of pathological response in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitor-based conversion therapy.

基于免疫检查点抑制剂的转化治疗对不可切除肝细胞癌病理缓解的预后意义

讲者：Wen-Jing Zheng 教授，复旦大学附属中山医院

摘要号：4141；壁报号：BD 431

Comparison outcome of transarterial chemoembolization combined with immune checkpoint inhibitors plus bevacizumab or lenvatinib as first-line therapy for advanced hepatocellular carcinoma.

经动脉化疗栓塞联合免疫检查点抑制剂加贝伐珠单抗或仑伐替尼一线治的疗晚期肝细胞癌疗效对比

摘要号：4144；壁报号：BD 434

Impact of radionuclide therapy on survival outcomes for de novo metastatic gastroenteropancreatic neuroendocrine tumors: A population-based cohort study.

放射性核素治疗对初发转移性胃肠胰神经内分泌肿瘤生存结局的影响：一项基于人群的队列研究

讲者：Zhiqiao Liu 教授，西南医科大学附属医院

摘要号：4157；壁报号：BD 447

Efficacy and safety of surufatinib (S) plus KN046 (K) and chemotherapy in first line (1L) advanced pancreatic cancer (PC): A single-arm, phase 1b/2 trial.

索凡替尼（S）联合KN046（K）及化疗一线治疗晚期胰腺癌（PC）的疗效与安全性：一项单臂Ib/II期试验

讲者：王文权教授，复旦大学附属中山医院

摘要号：4159；壁报号：BD 449

TQB2868 combined with anlotinib and nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.

TQB2868联合安罗替尼、白蛋白紫杉醇及吉西他滨一线治疗转移性胰腺癌：一项前瞻性多中心单臂II期研究

讲者：施思教授，复旦大学附属肿瘤医院

摘要号：4160；壁报号：BD 450

Phase II trial of serplulimab combined with gemcitabine plus nab-paclitaxel (GnP) and SBRT for metastatic pancreatic cancer as the first-line treatment.

斯鲁利单抗联合吉西他滨+白蛋白紫杉醇（GnP）及立体定向放疗（SBRT）一线治疗转移性胰腺癌的II期试验

讲者：成科教授，四川大学华西医院

摘要号：4161；壁报号：BD 451

First-line treatment with surufatinib, camrelizumab, nab-paclitaxel, and S-1 in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase Ib/II randomized study.

索凡替尼、卡瑞利珠单抗、白蛋白紫杉醇及S-1一线治疗局部晚期或转移性胰腺导管腺癌（PDAC）：一项Ib/II期随机研究

讲者：戴广海教授，中国人民解放军总医院第五医学中心

摘要号：4162；壁报号：BD 452

First-line serplulimab and bevacizumab combined with nab-paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer: A phase II trial.

一线斯鲁利单抗联合贝伐珠单抗、白蛋白紫杉醇/吉西他滨序贯mFOLFOX治疗晚期胰腺癌的II期研究

讲者：应杰儿教授，浙江省肿瘤医院

摘要号：4165；壁报号：BD 455

Homologous recombination deficiency (HRD) profiling in Chinese pancreatic ductal adenocarcinoma: Implications for platinum-based chemotherapy.

中国胰腺导管腺癌同源重组缺陷（HRD）特征及其对以铂类为基础化疗的指导意义

讲者：Yanxia Wang 教授，中山大学附属第一医院

摘要号：4174；壁报号：BD 464

USP22 as promoter of Treg cell infiltration and modulator of immunotherapy efficacy through the PIAS1/P65/CCL22 pathway in pancreatic cancer.

USP22通过PIAS1/P65/CCL22通路促进胰腺癌Treg细胞浸润并调节免疫治疗疗效

讲者：王阿曼教授，大连医科大学附属第一医院

摘要号：4188；壁报号：BD 478

Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine and nab-paclitaxel in patients with Claudin18.2-positive, locally advanced, unresectable, or metastatic pancreatic cancer.

FG-M108联合吉西他滨及白蛋白紫杉醇治疗Claudin18.2阳性局部晚期/不可切除或转移性胰腺癌的Ib期研究初步结果

讲者：刘福囝教授，中国医科大学附属第一医院

摘要号：4191；壁报号：BD 481

Development and prospective validation of a novel cfDNA-based diagnostic model for the early detection of pancreatic cancer.

基于cfDNA的新型胰腺癌早期诊断模型的开发与前瞻性验证

讲者：王秀超教授，天津医科大学肿瘤医院

摘要号：4192；壁报号：BD 482

Prognostic value of postoperative circulating tumor DNA and tumor markers in resected pancreatic adenocarcinoma (PAAD): An interim analysis of a prospective observational study.

术后ctDNA与肿瘤标志物对胰腺癌（PAAD）切除患者的预后价值：一项前瞻性观察性研究中期分析

讲者：詹茜教授，上海交通大学医学院附属瑞金医院

摘要号：TPS 4220；壁报号：BD 500b

A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE.

阿得贝利单抗联合卡培他滨术后辅助治疗伴高危因素胆管癌的2期随机多中心研究（ACHIEVE）

讲者：李相成教授，南京医科大学第一附属医院

摘要号：TPS 4223；壁报号：BD 502a

Donafenib combined with capecitabine for postoperative adjuvant therapy of biliary malignant tumors with high risk of recurrence: A multi-center, randomized controlled, phase II study.

多纳非尼联合卡培他滨术后辅助治疗高复发风险胆道恶性肿瘤：一项多中心随机对照II期研究

摘要号：TPS 4228；壁报号：BD 504b

ALTER-PA001: A multicenter, randomized study of anlotinib and benmelstobart in combination with AG chemotherapy vs. AG as first-line treatment for metastatic pancreatic cancer.

ALTER-PA001：安罗替尼联合贝莫苏拜单抗及AG化疗对比AG一线治疗转移性胰腺癌的多中心随机研究。

讲者：崔玖洁教授，上海交通大学医学院附属仁济医院

症状科学及姑息治疗专场

Symptom Science and Palliative Care

美国东部时间：6月2日13:30

北京时间：6月3日02:30

地点：Hall A

摘要号：12085；壁报号：BD 105

Effectiveness and safety of multimodal analgesic management based on the ERAS concept in the perioperative period of TACE for patients with Intermediate and advanced hepatocellular carcinoma.

基于加速康复外科（ERAS）理念的多模式镇痛管理在中晚期肝细胞癌患者经动脉化疗栓塞（TACE）围手术期应用有效性与安全性

讲者：Yanqin Wu 教授，中山大学附属第一医院

治疗策略进展——免疫治疗

Developmental Therapeutics—Immunotherapy

摘要号：2585；壁报号：BD 232

Role of p57 in cGAS-STING-mediated innate sensing and immunotherapy response in hepatocellular carcinoma.

p57在cGAS-STING介导的肝细胞癌先天免疫识别及免疫治疗应答中的作用

讲者：Shirong Zhang 教授，西安交通大学第一附属医院

摘要号：2607；壁报号：BD 254

Outcomes of conversion surgery after immune checkpoint inhibitor-based combination therapy in initially unresectable hepatocellular carcinoma: A retrospective cohort study.

基于免疫检查点抑制剂的联合治疗后行转化手术对初始不可切除肝细胞癌的疗效：一项回顾性队列研究

讲者：Mingjian Piao 教授，北京协和医院

治疗策略进展——分子靶向治疗药物及肿瘤生物学

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

摘要号：3088；壁报号：BD 403

The effect of HIFU treatment on liver metastasis of colorectal cancer in mice and its impact on immunity.

高强度聚焦超声（HIFU）治疗对小鼠结直肠癌肝转移的影响及其免疫调节作用

Presenter: Shasha Wang, MD | Department of Medical Oncology, Affiliated Hospital of Qingdao University

讲者：王莎莎教授，青岛大学附属医院

摘要号：3137；壁报号：BD 452

Multi-omics cohort-based prediction model for early relapse of hepatocellular carcinoma post-surgery.

基于多组学队列构建的肝细胞癌术后早期复发预测模型。